Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 27, 2012, by Jazz Pharmaceuticals Public Limited Company, an Ireland-based pharmaceutical company. The report details executive compensation arrangements approved on July 27, 2012, and the results of the Company's 2012 Annual General Meeting of Shareholders held on the same date.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance, equity grants, and shareholder voting results.
Material Changes and Executive Compensation
On July 27, 2012, the Board of Directors approved grants of stock options and restricted stock units (RSUs) under the 2011 Equity Incentive Plan to named executive officers. The grants are effective on the first day of the next open trading window.
| Named Executive Officer | Stock Options (Shares) | RSUs (Shares) |
|---|---|---|
| Bruce C. Cozadd (Chairman & CEO) | 200,000 | 100,000 |
| Kathryn E. Falberg (EVP & CFO) | 70,000 | 35,000 |
| Russell J. Cox (EVP & Chief Commercial Officer) | 70,000 | 35,000 |
| Karen J. Wilson (VP, Finance & PAO) | 30,000 | 15,000 |
Terms: Options have a 10-year term with a 4-year vesting schedule (25% after one year, remainder monthly). RSUs vest annually over four years. Both awards include full acceleration provisions in the event of a change in control or termination without cause within 12 months of such an event.
Shareholder Voting Results
Shareholders representing 51,766,909 of 56,900,979 entitled shares voted on four proposals:
- Proposal 1 (Election of Directors): Kenneth W. O'Keefe and Catherine A. Sohn, Pharm.D., were elected as Class I directors. Alan M. Sebulsky resigned and did not stand for re-election.
- Proposal 2 (Auditor Ratification): Approval of KPMG as independent auditors for fiscal year 2012 was approved (51,672,203 For).
- Proposal 3 (Say-on-Pay): Advisory approval of executive compensation was approved (43,525,000 For).
- Proposal 4 (Say-on-Pay Frequency): Shareholders indicated a preference for an annual advisory vote (25,583,426 votes for "1 Year").
Corporate Governance and Compliance
Following the resignation of director Alan M. Sebulsky, the Company received notice from NASDAQ regarding non-compliance with audit committee composition rules (requiring three independent members). On July 27, 2012, the Board appointed Paul L. Berns as the third independent member of the Audit Committee. NASDAQ confirmed compliance on July 30, 2012, closing the matter.
Investor Verification Checklist
- Verify the exact "Grant Date" for the executive stock options and RSUs, as the filing states they will be effective on the first day of the next open trading window.
- Review the definitive proxy statement (Schedule 14A) filed on June 14, 2012, for detailed biographical information on the newly elected directors and full compensation disclosure.
- Confirm the specific terms of the "Change in Control" and "Severance Plan" referenced in the filing to understand acceleration triggers.
- Monitor future filings for the actual issuance of shares corresponding to the approved grants.